Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine and Epirubicin for the Treatment of Mesothelioma
NCT00017186Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Jul 2001
- Primary completion
- Aug 2004
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of gemcitabine, epirubicin in malignant pleural mesothelioma (MPM), sponsored by Cancer and Leukemia Group B. Started Jul 2001; status: completed.
02
Drugs
gemcitabineepirubicin
03
Conditions
malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT00017186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00017186.